Lilly CEO: On Track to Hit 2018 Operating Expense Goal

Eli Lilly reported a slight miss in Q1 profits but showed a 5% revenue growth, or 8% when adjusted for currency. The growth was driven by new product sales despite a decline in Humalog sales. The company is focusing on innovation to counteract patent expirations. Upcoming drugs include Layer two Mab and baricitinib, with several others in phase three development. Eli Lilly aims to keep operating expenses below 50% of revenue by 2018, driven by revenue growth and expense control.

Which new medicines has Eli Lilly launched since 2014?

What are the goals Eli Lilly has set for operating expenses by 2018?